Total Payments
$10,128
2024 Payments
$1,320
Companies
46
Transactions
708
Medicare Patients
17,717
Medicare Billing
$736,896
Payment Breakdown by Category
Food & Beverage$9,943 (98.2%)
Education$184.64 (1.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,943 | 701 | 98.2% |
| Education | $184.64 | 7 | 1.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,986 | 61 | $0 (2024) |
| PFIZER INC. | $1,184 | 80 | $0 (2024) |
| Amgen Inc. | $928.81 | 93 | $0 (2024) |
| ABBVIE INC. | $901.73 | 72 | $0 (2024) |
| Novo Nordisk Inc | $706.76 | 61 | $0 (2024) |
| Lilly USA, LLC | $472.96 | 42 | $0 (2024) |
| Merck Sharp & Dohme LLC | $383.44 | 34 | $0 (2024) |
| Astellas Pharma US Inc | $367.08 | 19 | $0 (2024) |
| Allergan, Inc. | $319.99 | 35 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $288.95 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,320 | 74 | AstraZeneca Pharmaceuticals LP ($422.38) |
| 2023 | $1,028 | 70 | AbbVie Inc. ($245.21) |
| 2022 | $1,196 | 82 | Biohaven Pharmaceutical Holding Company Ltd. ($222.62) |
| 2021 | $1,749 | 119 | AstraZeneca Pharmaceuticals LP ($294.38) |
| 2020 | $977.40 | 68 | AstraZeneca Pharmaceuticals LP ($316.93) |
| 2019 | $1,245 | 109 | PFIZER INC. ($341.54) |
| 2018 | $975.87 | 62 | AstraZeneca Pharmaceuticals LP ($168.18) |
| 2017 | $1,637 | 124 | AstraZeneca Pharmaceuticals LP ($339.33) |
All Payment Transactions
708 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: Biological | ||||||
| 12/05/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), VAXNEUVANCE, CAPVAXIVE | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: VACCINE | ||||||
| 11/27/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: Inflammation | ||||||
| 11/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.95 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.93 | General |
| 11/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.21 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.45 | General |
| 10/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: Cardio-renal | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.07 | General |
| Category: Cardiovascular | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), VAXNEUVANCE, CAPVAXIVE | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: VACCINE | ||||||
| 10/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: PAIN | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.24 | General |
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Education | In-kind items and services | $46.24 | General |
| Category: Respiratory | ||||||
| 10/03/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.95 | General |
| Category: Cardiovascular | ||||||
| 09/17/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: PAIN | ||||||
| 09/11/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.33 | General |
| 09/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/28/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: PAIN | ||||||
| 08/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: NEUROSCIENCE | ||||||
| 08/12/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: Biological | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 4,061 | 9,094 | $503,960 | $140,237 |
| 2022 | 42 | 4,417 | 9,813 | $509,386 | $143,007 |
| 2021 | 44 | 4,630 | 11,062 | $611,714 | $238,503 |
| 2020 | 45 | 4,609 | 10,434 | $596,941 | $215,149 |
Total Patients
17,717
Total Services
40,403
Medicare Billing
$736,896
Procedure Codes
170
All Medicare Procedures & Services
170 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 17 | 1,860 | $62,280 | $33,974 | 54.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 331 | 818 | $217,565 | $32,879 | 15.1% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 312 | 491 | $18,167 | $6,416 | 35.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 336 | 756 | $7,347 | $6,199 | 84.4% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 269 | 354 | $13,452 | $5,827 | 43.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 319 | 562 | $16,298 | $5,796 | 35.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 318 | 584 | $12,264 | $4,429 | 36.1% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2023 | 15 | 15 | $5,556 | $3,792 | 68.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 220 | 220 | $4,400 | $3,736 | 84.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 87 | $16,202 | $3,291 | 20.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 56 | 68 | $25,402 | $3,258 | 12.8% |
| 82306 | Vitamin d-3 level | Office | 2023 | 91 | 107 | $8,667 | $3,104 | 35.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 100 | 101 | $6,759 | $2,866 | 42.4% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 149 | 292 | $7,300 | $2,761 | 37.8% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2023 | 242 | 423 | $5,076 | $2,585 | 50.9% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 15 | 327 | $9,483 | $2,506 | 26.4% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 101 | 102 | $3,198 | $2,208 | 69.0% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 243 | 425 | $5,950 | $2,159 | 36.3% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 76 | 95 | $8,140 | $1,941 | 23.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 60 | 195 | $13,027 | $1,709 | 13.1% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 282 | 519 | $4,671 | $1,611 | 34.5% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 20 | 27 | $4,818 | $1,055 | 21.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 16 | 16 | $4,544 | $865.26 | 19.0% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 60 | 89 | $1,691 | $786.76 | 46.5% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 33 | 33 | $1,485 | $624.36 | 42.0% |
About Dr. Thomas Wente, DO
Dr. Thomas Wente, DO is a Family Medicine healthcare provider based in South Sioux City, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538134002.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Wente, DO has received a total of $10,128 in payments from pharmaceutical and medical device companies, with $1,320 received in 2024. These payments were reported across 708 transactions from 46 companies. The most common payment nature is "Food and Beverage" ($9,943).
As a Medicare-enrolled provider, Wente has provided services to 17,717 Medicare beneficiaries, totaling 40,403 services with total Medicare billing of $736,896. Data is available for 4 years (2020–2023), covering 170 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location South Sioux City, NE
- Active Since 02/20/2006
- Last Updated 12/03/2025
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1538134002
Products in Payments
- FARXIGA (Drug) $1,029
- ELIQUIS (Drug) $813.95
- VRAYLAR (Drug) $460.54
- UBRELVY (Drug) $431.64
- BREZTRI (Drug) $415.72
- NURTEC ODT (Drug) $358.51
- EVENITY (Biological) $355.08
- Aimovig (Biological) $213.46
- Tresiba (Drug) $208.37
- JARDIANCE (Drug) $188.93
- Prolia (Biological) $180.94
- EMGALITY (Drug) $177.00
- Ozempic (Drug) $173.69
- NEXLETOL (Drug) $170.70
- Kerendia (Drug) $163.02
- MYDAYIS (Drug) $159.81
- BYDUREON (Drug) $156.72
- Vascepa (Drug) $154.92
- Otezla (Drug) $148.23
- CHANTIX (Drug) $142.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in South Sioux City
Dr. Michael Brenner, M.d, M.D
Family Medicine — Payments: $17,646
Family Medicine $17,646
Michael Hattan, Md, MD
Family Medicine — Payments: $11,240
Family Medicine $11,240
Melissa Austreim-Krell, M.d, M.D
Family Medicine — Payments: $8,652
Family Medicine $8,652
David Ensz, M.d, M.D
Family Medicine — Payments: $7,676
Family Medicine $7,676
Suhair Najdawi, Md, MD
Family Medicine — Payments: $4,040
Family Medicine $4,040
Austin Granatowicz, Md, MD
Family Medicine — Payments: $2,343
Family Medicine $2,343